Coherus BioSciences, Inc.

NasdaqGM CHRS

Coherus BioSciences, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 43.48%

Coherus BioSciences, Inc. Gross Profit Margin is 43.48% for the Trailing 12 Months (TTM) ending September 30, 2024, a -25.05% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Coherus BioSciences, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 58.01%, a -18.94% change year over year.
Coherus BioSciences, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 71.56%, a -15.09% change year over year.
Coherus BioSciences, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 84.28%, a -9.47% change year over year.
Coherus BioSciences, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 93.09%, a 10.14% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGM: CHRS

Coherus BioSciences, Inc.

CEO	Mr. Dennis M. Lanfear
IPO Date	Nov. 6, 2014
Location	United States
Headquarters	333 Twin Dolphin Drive
Employees	235
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Key trends

Past 5 years